Is Innoviva Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: INVA) stock is to Strong Buy INVA stock.
Out of 2 analysts, 1 (50%) are recommending INVA as a Strong Buy, 1 (50%) are recommending INVA as a Buy, 0 (0%) are recommending INVA as a Hold, 0 (0%) are recommending INVA as a Sell, and 0 (0%) are recommending INVA as a Strong Sell.
What is INVA's earnings growth forecast for 2025-2025?
(NASDAQ: INVA) Innoviva's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Innoviva's earnings in 2025 is -$59,724,000.
In 2025, INVA is forecast to generate $97,301,518 in earnings, with the lowest earnings forecast at $97,301,518 and the highest earnings forecast at $97,301,518.
What is INVA's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: INVA) forecast ROE is 15.04%, which is considered weak.
What is INVA's Price Target?
According to 2 Wall Street analysts that have issued a 1 year INVA price target, the average INVA price target is $40.50, with the highest INVA stock price forecast at $55.00 and the lowest INVA stock price forecast at $26.00.
On average, Wall Street analysts predict that Innoviva's share price could reach $40.50 by Jul 11, 2026. The average Innoviva stock price prediction forecasts a potential upside of 115.77% from the current INVA share price of $18.77.
What is INVA's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: INVA) Innoviva's current Earnings Per Share (EPS) is -$0.95. In 2025, INVA's EPS is forecast to hit $1.55 (min: $1.55, max: $1.55).
What is INVA's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: INVA) forecast ROA is 7.76%, which is higher than the forecast US Biotechnology industry average of -0.44%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.